Stock comparison
IDEXX Laboratories
The Pennant Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
PNTG
The Pennant Group
Market cap
$1.19B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | PNTG | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 59C | IDXX |
| Benjamin Graham | 72B | 76B | PNTG |
| Philip Fisher | 67B | 59C | IDXX |
| Peter Lynch | 63C | 50C | IDXX |
| Joel Greenblatt | 75B | 43D | IDXX |
| Charlie Munger | 79B | 38D | IDXX |
| Terry Smith | 76B | 35D | IDXX |
Side-by-side metrics
| Metric | IDXX | PNTG |
|---|---|---|
| Market cap | $42.11B | $1.19B |
| P/E (TTM) | 39.0x | 39.1x |
| EV/EBIT | 31.6x | 31.7x |
| ROIC (TTM) | 40.66% | 4.96% |
| Gross margin | 62.05% | 14.78% |
| Net margin | 24.63% | 2.96% |
| Revenue CAGR 5y | 7.56% | 21.17% |
| EPS CAGR 5y | 10.79% | 83.65% |
| Debt / Equity | 0.7x | 1.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $1.19B+97%
- Net margin24.63%vs 2.96%+88%
- ROIC (TTM)40.66%vs 4.96%+88%
- Gross margin62.05%vs 14.78%+76%
PNTG leads on
- EPS CAGR 5y83.65%vs 10.79%+87%
- Revenue CAGR 5y21.17%vs 7.56%+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.